Only in Titles

Search results for: Annexin V PE Apoptosis Detection Kit100 assays

paperclip

#32355771   // To Up

Morusin exerts anti-cancer activity in renal cell carcinoma by disturbing MAPK signaling pathways.

Renal cell carcinoma (RCC) has gradually become a severe type of kidney malignant tumor, which warrants an urgent need for highly efficacious therapeutic agents. Morusin, a typical prenylated flavonoid, has been revealed to possess anticarcinogenic effects against several cancers by inhibiting cell proliferation and tumorigenesis.
Chengfei Yang, Jing Luo, Xing Luo, Weisheng Jia, Zhenqiang Fang, Shanhong Yi, Longkun Li

2291 related Products with: Morusin exerts anti-cancer activity in renal cell carcinoma by disturbing MAPK signaling pathways.



Related Pathways

paperclip

#29272788   2017/12/27 To Up

Combination of novel DR5 targeting agonistic scFv antibody TR2-3 with cisplatin shows enhanced synergistic antitumor activity in vitro and in vivo.

To investigate the antitumor activity of a novel agonistic single chain fragment variable (scFv) antibody TR2-3 targeting death receptor 5 (DR5) combined with cisplatin in vitro and in vivo.
Gaoxin Lei, Menglong Xu, Zhipan Xu, Chenchen Lu, Shuhua Tan

1649 related Products with: Combination of novel DR5 targeting agonistic scFv antibody TR2-3 with cisplatin shows enhanced synergistic antitumor activity in vitro and in vivo.

1 Set100ug1 Set1 Set1 Set100ug1-8 Sample Kit100ug4 Membranes/Box1 Set

Related Pathways

paperclip

#28953230   2017/09/27 To Up

A Novel Fully Human Agonistic Single Chain Fragment Variable Antibody Targeting Death Receptor 5 with Potent Antitumor Activity In Vitro and In Vivo.

Agonistic antibodies, which bind specifically to death receptor 5 (DR5), can trigger apoptosis in tumor cells through the extrinsic pathway. In this present study, we describe the use of a phage display to isolate a novel fully human agonistic single chain fragment variable (scFv) antibody, which targets DR5. After five rounds of panning a large (1.2 × 10⁸ clones) phage display library on DR5, a total of over 4000 scFv clones were screened by the phage ELISA. After screening for agonism in a cell-viability assay in vitro, a novel DR5-specific scFv antibody TR2-3 was isolated, which inhibited COLO205 and MDA-MB-231 tumor cell growth without any cross-linking agents. The activity of TR2-3 in inducing apoptosis in cancer cells was evaluated by using an Annexin V-PE apoptosis detection kit in combination with flow cytometry and the Hoechst 33342 and propidium iodide double staining analysis. In addition, the activation of caspase-dependent apoptosis was evaluated by Western blot assays. The results indicated that TR2-3 induced robust apoptosis of the COLO205 and MDA-MB-231 cells in a dose-dependent and time-dependent manner, while it remarkably upregulated the cleavage of caspase-3 and caspase-8. Furthermore, TR2-3 suppressed the tumor growth significantly in the xenograft model. Taken together, these data suggest that TR2-3 exhibited potent antitumor activity both in vitro and in vivo. This work provides a novel human antibody, which might be a promising candidate for cancer therapy by targeting DR5.
Gaoxin Lei, Menglong Xu, Zhipan Xu, Lili Gu, Chenchen Lu, Zhengli Bai, Yue Wang, Yongbo Zhang, Huajing Hu, Yiwei Jiang, Wenfeng Zhao, Shuhua Tan

2699 related Products with: A Novel Fully Human Agonistic Single Chain Fragment Variable Antibody Targeting Death Receptor 5 with Potent Antitumor Activity In Vitro and In Vivo.

50ul50 ug 100ul96T50ul50ul50ul50ug100ug Lyophilized 100ul100ug Lyophilized100ug Lyophilized

Related Pathways

paperclip

Error loading info... Pleas try again later.